First line choice in melanoma: immunotherapy or target therapy? We asked Omid Hamid, Director of Melanoma Therapeutics of The Angeles Clinic and Research Institute of Santa Monica. And what about monotherapy? In which patients we could use this therapeutical approach? From the Immunotherapy & Melanoma Bridge 2017 held in Naples.
Andare in bici, per un oncologo come me, è una metafora della bellezza e delle difficoltà del nostro lavoro.